The National Ataxia Foundation awarded Michael A. Walters, ITDD Director of Lead and Probe Discovery, a $100,000 grant for the project "Small Molecule Inhibitors of PKA: A Therapeutic Strategy for SCA 1." The main objective of this work is to discover compounds that can modulate the activity of PKA with the goal of developing a treatment for spinocerebellar ataxia. He also received a $390,690 R21 grant for the project "Development of antl-DUX4 therapeutics for FSHD" from the NIH NINDS. The main objective of this work is to discover, characterize, and develop anti-DUX4/D4Z4 therapeutics to treat facioscapulohumeral muscular dystrophy (FSHD).